In October 2022, we have identified the following collaborations and product launches/ approvals that caught our attention from the diagnostics perspective. Check them out:
Collaborations:
1. Illumina, AstraZeneca Partner on AI-Based Drug Target Discovery
The 2 firms will join forces on artificial intelligence-based genome interpretation and genomic analysis and evaluate whether a combined framework can increase the yield of and confidence in target discovery.
2. Biora Therapeutics Sells Cell-Free DNA Patents to Roche Diagnostics
Biora Therapeutics, formerly known as Progenity, said on Thursday that it has sold certain patent rights related to determining the origin of cell-free DNA to Roche Diagnostics. Financial and other terms of the deal were not disclosed.
3. Invitae Announces Partnership for Real-World Data Sharing to Inform Rare Cancer Research
This partnership will enable sharing of high-quality, patient-consented data from the patient community of the Cholangiocarcinoma Foundation (CCF), a leading patient advocacy group whose mission is to find a cure and improve the quality of life for those with cholangiocarcinoma.
4. BioIntelliSense buys AlertWatch, expanding Medtronic patient monitoring partnership
BioIntelliSense has acquired clinical intelligence and triage system AlertWatch to expand the set of technologies distributed in the U.S. through its partnership with Medtronic. AlertWatch sells a dashboard that aggregates data to give clinicians an overview of patient vital sign trends.
This alliance will enable global access to a package combining Illumina sequencing products and the GenoScreen Deeplex® Myc-TB assay, a targeted next-generation sequencing (NGS) based test for rapid and extensive detection of anti-TB drug resistance, to promptly inform treatment decision.
6. GE Healthcare, AMC Health Announce Remote Patient Monitoring Collab
The partnership will extend the continuum of nonacute care for patients after they are discharged from the hospital.
7. Brainomix and NCIMI collaborate on automated cancer tracking tool
Brainomix, the AI-powered medtech solutions company, is collaborating with the National Consortium of Intelligent Medical Imaging (NCIMI, hosted at the University of Oxford) and three selected NHS sites on a project to optimise and validate its automated cancer tracking tool, e-ACT.
The partners will define cutting-edge research topics at the intersection of health and applications of AI, which will be selected by a joint steering committee.
Product launches/ approvals
1. Roche wins FDA approval for companion diagnostic to support breast cancer therapy
Roche has received approval from the Food and Drug Administration for the first companion diagnostic to identify patients with HER2-low metastatic breast cancer. The approval of Roche’s test comes two months after AstraZeneca and Daiichi Sankyo’s Enhertu became the first therapy authorized for use in HER2-low breast cancer in the U.S.
The new test, designed for the analysis of stool samples and the detection of a range of common gastrointestinal bacteria, relies on polymerase chain reaction (PCR) technology.
Program aims to help individuals identify flu symptoms using wearables and algorithms developed to characterize influenza-like-illness; Almost 90,000 individuals are already enrolled for 2022 flu season
4. Ophiomics Liver Cancer Assay Gets CE-IVD Mark
Biocartis announced on Monday Ophiomics has received CE-IVD marking for the HepatoPredict prognostic liver cancer assay to identify which patients would benefit most from a liver transplant.
5. Roche launches next generation of rapid antigen tests
Roche builds upon its portfolio of COVID-19 rapid testing solutions with three new test configurations that feature an improved capture antibody and the addition of new digital data sharing capabilities to all tests.
Cytomegalovirus infection can cause significant morbidity in transplant recipients and other immunocompromised individuals. The recently developed PlexAPR™ test predicts transplant rejection and also reports results within 6 hours